What Are Signs of a Yervoy Overdose?
Yervoy (ipilimumab), an immunotherapy drug for melanoma and other cancers, has no specific antidote for overdose. Management focuses on supportive care and monitoring for severe immune-related reactions, as toxicity stems from excessive immune activation rather than direct organ damage. No dedicated overdose symptoms are distinctly listed in prescribing information; instead, signs overlap with common or severe adverse reactions amplified in intensity.[1][2]
Common Side Effects That Could Worsen in Overdose
Patients on standard Yervoy doses (typically 1-10 mg/kg IV every 3 weeks) often experience:
- Fatigue, diarrhea, itching, or rash—these fatigue or intensify first in potential overdose scenarios.
- Nausea, vomiting, or fever, which may signal early immune overactivation.[1]
Severe Immune-Related Reactions Mimicking Overdose
Overdose risks heighten these grade 3-4 events, occurring in up to 40% of patients on higher doses:
- Gastrointestinal: Colitis with severe diarrhea (up to 10 bloody stools/day), abdominal pain, or perforation—most common severe effect (7-10% incidence).[1][2]
- Skin: Life-threatening rash or Stevens-Johnson syndrome.
- Endocrine: Hypophysitis (pituitary inflammation) causing adrenal crisis, hypothyroidism, or hyperglycemia.
- Hepatic: Hepatitis with elevated liver enzymes (up to 10x normal).
- Pulmonary: Pneumonitis or interstitial lung disease.
- Neurologic: Encephalitis, myasthenia gravis, or Guillain-Barré syndrome (rare but fatal).[1][3]
In trials, a 10 mg/kg overdose case showed no unexpected toxicities beyond expected immune effects, treated with steroids and observation.[2]
What Happens If You Suspect Overdose?
Discontinue Yervoy immediately. Administer high-dose corticosteroids (1-2 mg/kg/day methylprednisolone IV), escalate to immunosuppressants like infliximab for refractory cases, and monitor vital signs, electrolytes, and organ function in ICU if needed. Report to FDA MedWatch.[1][2]
How Common Are Overdose Events?
Rare in clinical use due to controlled IV dosing in oncology settings. No large-scale data on accidental overdoses; risks rise with combination therapy (e.g., Yervoy + Opdivo), where adverse events hit 50-60%.[3]
Differences from Standard Side Effects
Standard effects are milder and reversible with dose holds; overdose amplifies to organ-threatening levels within days, often requiring permanent discontinuation.[1]
Sources
[1]: Yervoy Prescribing Information (Bristol Myers Squibb)
[2]: FDA Label for Ipilimumab
[3]: Drugs.com - Yervoy Side Effects